Clinical Trials Browser

Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies

NCT07085767 2026-04-16

OPERA-02

Phase 3 Recruiting

1,000 enrolled

Breast

Breast Neoplasms

NCT05238922 2026-04-14

Study of INCB123667 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

604 enrolled

BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

NCT05358249 2026-04-14

KontRASt-03

Phase 1/2 Active not recruiting

74 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT05827081 2026-04-14

Adjuvant WIDER

Phase 3 Recruiting

1,400 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT06380751 2026-04-14

EvoPAR-BR01

Phase 3 Recruiting

500 enrolled

Breast

Advanced Breast Cancer

NCT04802759 2026-04-13

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Phase 1/2 Recruiting

316 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05038631 2026-04-13

Managed Access Programs for LEE011, Ribociclib

Available

Breast

Breast Neoplasms

NCT06625775 2026-04-13

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

392 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT06188520 2026-04-08

CYCAD-1

Phase 1/2 Recruiting

564 enrolled

BreastGynecologic

ER+ HER2- Advanced Breast Cancer

NCT05203172 2026-04-07

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

Phase 4 Recruiting

46 enrolled

Other solid neoplasm

Solid Tumors

NCT06065748 2026-04-06

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Phase 3 Recruiting

1,050 enrolled

Breast

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT05161195 2026-04-02

Roll-over Study to Allow Continued Access to Ribociclib

Phase 4 Active not recruiting

134 enrolled

Breast

Breast Neoplasms

NCT07340658 2026-04-02

SIE-3

Phase 3 Not yet recruiting

300 enrolled

Breast

Breast Neoplasms

NCT01872260 2026-04-01

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

Phase 1/2 Active not recruiting

255 enrolled

Breast

Breast Neoplasms

NCT03701334 2026-04-01

NATALEE

Phase 3 Active not recruiting

5,101 enrolled 3 FDA

Breast

Breast Neoplasms

NCT04943497 2026-04-01

PROSPERITY

Completed

2,424 enrolled

Breast

Breast Neoplasms

NCT06830720 2026-04-01

CAROLEEN

Recruiting

3,250 enrolled

Breast

Breast Neoplasms

NCT06905301 2026-04-01

IMPULSE

Recruiting

240 enrolled

Breast

Breast Neoplasms

NCT07054190 2026-03-31

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

Phase 2 Recruiting

60 enrolled

Breast

Breast Neoplasms

NCT07492641 2026-03-25

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

Phase 3 Not yet recruiting

1,056 enrolled

Breast

HR+/HER2- Breast Cancer

Clinical Trials

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

SERENA-6

CAPItello-292

ELEGANCE

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Ribociclib (LEE011) Rollover Study for Continued Access

OPERA-02

Study of INCB123667 in Subjects With Advanced Solid Tumors

KontRASt-03

Adjuvant WIDER

EvoPAR-BR01

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Managed Access Programs for LEE011, Ribociclib

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

CYCAD-1

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Roll-over Study to Allow Continued Access to Ribociclib

SIE-3

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

NATALEE

PROSPERITY

CAROLEEN

IMPULSE

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease